Purple Biotech Advances Oncology Frontiers Positive Pancreatic Cancer Trial Results and New Head and Neck Cancer...

Published / Modified Jul 10 2024
CSIMarket Team / CSIMarket.com

Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company based in Rehovot, Israel, is making significant strides in oncology, with encouraging interim results from their Phase 2 pancreatic cancer study and a key dose determination for their head and neck cancer treatment. These advancements mark critical milestones for the company, emphasizing their commitment to developing first-in-class therapeutic options that tackle tumor immune evasion and drug resistance.

Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24

Purple Biotech recently announced positive interim results from their Phase 2 study evaluating CM24 in combination with nivolumab for pancreatic cancer. To discuss these promising findings, the company will host a virtual key opinion leader (KOL) event on July 11, 2024, at 10:30 AM ET. The study places a strong focus on CM24, an anti-CEACAM1 monoclonal antibody that has shown potential in bolstering immune response against tumors.

Pancreatic cancer remains one of the most challenging malignancies to treat, often leading to late-stage diagnosis and poor overall survival rates. Achieving favorable outcomes in interim results is a significant achievement, paving the way for more comprehensive understanding and potential therapies in pancreatic oncology.

Recommended Phase 2 Dose for NT219

Earlier this year, Purple Biotech announced the recommended Phase 2 dose (RP2D) for NT219, a small molecule dual inhibitor of IRS1/2 and STAT3. The RP2D determination follows Phase 1/2 dose escalation studies (NCT04474470) targeting head and neck cancers, particularly in combination with cetuximab, an EGFR inhibitor. The RP2D for NT219 has been established at 100mg/kg.

The combination therapy aims to target and inhibit critical pathways in tumor cell survival and proliferation. IRS1/2 (Insulin Receptor Substrate 1 and 2) and STAT3 (Signal Transducer and Activator of Transcription 3) contribute to promoting tumor growth and evading the immune system's defenses. By inhibiting these pathways, NT219 can potentially enhance the efficacy of existing treatments like cetuximab, providing a more robust and multi-faceted approach to combating cancer.

Impact on Purple Biotech and Oncology Landscape

These recent developments underscore Purple Biotech?s potential to deliver innovative cancer therapies. Positive interim results from the Phase 2 pancreatic cancer study bode well for further clinical phases and eventual regulatory approval. Additionally, the establishment of RP2D for NT219 represents substantial progress in optimizing treatment regimens for head and neck cancers, enhancing both safety and efficacy profiles.

For Purple Biotech, these advancements not only strengthen their clinical pipeline but also validate their strategic focus on harnessing the tumor microenvironment. The anti-CEACAM1 approach of CM24 and the dual inhibition mechanism of NT219 showcase Purple Biotech?s innovative methodologies, which may offer new hope for patients with difficult-to-treat cancers.

As the company continues its clinical trials and prepares for future regulatory milestones, the oncology community eagerly anticipates further updates and detailed data. Success in these ventures could position Purple Biotech as a leading force in the oncology therapeutic landscape, advancing the frontier of cancer treatment and improving patient outcomes globally.

Sources for this article: Purple Biotech Ltd Press release, News Wire, Globe Newswire, Business wire, Pr newswire.... and CSIMarket.com Customer Analytics Research for Purple Biotech Ltd


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com